An anti-inflammatory DPP-4 (dipeptidyl peptidase-4) inhibitor (anagliptin) has been shown to reduce aneurysm growth through NF-κ-B and ERK5 signaling involving IL-6 [22,23]. Here, IL6 is linked to aneurysm.